Last reviewed · How we verify

mRNA-1273 — Competitive Intelligence Brief

mRNA-1273 (mRNA-1273) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mRNA vaccine. Area: Immunology / Infectious Disease.

marketed mRNA vaccine SARS-CoV-2 spike protein (S protein) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

mRNA-1273 (mRNA-1273) — Assistance Publique - Hôpitaux de Paris. mRNA-1273 is a lipid nanoparticle-formulated messenger RNA vaccine that encodes the SARS-CoV-2 spike protein, instructing cells to produce the antigen and trigger adaptive immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
mRNA-1273 TARGET mRNA-1273 Assistance Publique - Hôpitaux de Paris marketed mRNA vaccine SARS-CoV-2 spike protein (S protein)
mRNA-1273 Variant-containing Formulation mRNA-1273 Variant-containing Formulation ModernaTX, Inc. marketed mRNA vaccine SARS-CoV-2 spike protein (variant-specific)
BNT162b2 Pfizer-BioNTech/Comirnaty BNT162b2 Pfizer-BioNTech/Comirnaty KK Women's and Children's Hospital marketed mRNA vaccine SARS-CoV-2 spike protein (S protein)
Pfizer-COVID-19 Vaccine Pfizer-COVID-19 Vaccine National Heart, Lung, and Blood Institute (NHLBI) marketed mRNA vaccine SARS-CoV-2 spike protein (S protein)
The Pfizer mRNA-based BNT162b2 vaccine The Pfizer mRNA-based BNT162b2 vaccine dafna yahav marketed mRNA vaccine SARS-CoV-2 spike protein (S protein)
Comirnaty Omicron XBB.1.5 Comirnaty Omicron XBB.1.5 Jules Bordet Institute marketed mRNA vaccine SARS-CoV-2 spike protein (XBB.1.5 variant)
Moderna mRNA-1273 COVID-19 vaccine Moderna mRNA-1273 COVID-19 vaccine National Institute of Allergy and Infectious Diseases (NIAID) marketed mRNA vaccine SARS-CoV-2 spike protein (S protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mRNA vaccine class)

  1. Pfizer · 12 drugs in this class
  2. ModernaTX, Inc. · 11 drugs in this class
  3. BioNTech SE · 5 drugs in this class
  4. Jules Bordet Institute · 5 drugs in this class
  5. Tan Tock Seng Hospital · 2 drugs in this class
  6. Clover Biopharmaceuticals AUS Pty · 1 drug in this class
  7. CanSino Biologics Inc. · 1 drug in this class
  8. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  9. CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
  10. Jens D Lundgren, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). mRNA-1273 — Competitive Intelligence Brief. https://druglandscape.com/ci/mrna-1273. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: